Digital inhalers may help predict occurrence of acute exacerbations of COPD for patients in an ambulatory setting.

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

In a major positive step for global respiratory health, Member States at the 78th World Health Assembly (WHA), held May 19–27 ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.

Australians living with chronic obstructive pulmonary disease (COPD) are being exposed to greater health risks as the use of a critical diagnostic ...

Trelegy Ellipta, a triple-therapy inhaler containing an inhaled corticosteroid (ICS), a long-acting muscarinic antagonist (LAMA), and a long-acting beta-agonist (LABA), was found to offer ...

Metered-dose inhaler budesonide-glycopyrrolate-formoterol (Breztri Aerosphere) was associated with a higher risk of a first moderate or severe COPD exacerbation (HR 1.09, 95% CI 1.04-1.14 ...

One recent meta-analysis of clinical trials found that LABA/LAMA had a 42% higher risk of major adverse cardiovascular events (MACE') compared to another combination therapy of LABA and inhaled ...

Triple therapy in COPD involves long-acting β2-agonist, long-acting muscarinic antagonist, and inhaled corticosteroid (LABA/LAMA/ICS).

While this LABA/LAMA combination is nothing new, Barnes says that adding a third medicine—an inhaled corticosteroid— has proven helpful in patients with high blood levels of eosinophils.

There are several fixed-dose LABA/LAMA combination inhalers available — these are inhalers that contain both medications in one. These are currently the primary therapy for many people with COPD.

If your levels of eosinophils (a type of pro-inflammatory white blood cell) at or above 300 blood eosinophil units, it may be best to step up to LABA+LAMA as well as an inhaled corticosteroid (ICS ...